No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation-Reference-Cited by-同舟云学术

No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation

Published:2014-07-03 Issue:3 Volume:22 Page:585-587
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Eur J Neurol

Author:

Capobianco M.¹,di Sapio A.¹,Malentacchi M.¹,Malucchi S.¹,Matta M.¹,Sperli F.¹,Bertolotto A.¹

Affiliation:

1. Regional Multiple Sclerosis Centre; San Luigi Gonzaga Hospital; Orbassano Italy

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ene.12487/fullpdf

Reference10 articles.

1. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the natalizumab safety and efficacy in relapsing−remitting multiple sclerosis (AFFIRM) study;Havrdova;Lancet Neurol,2009

2. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab;Soelberg Sorensen;Mult Scler,2012

3. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis;O'Connor;Neurology,2011

4. Clinical and radiological disease reactivation after cessation of long-term therapy with natalizumab;Baumgartner;Int J Neurosci,2012

5. Natalizumab drug holiday in multiple sclerosis: poorly tolerated;Killlestein;Ann Neurol,2010

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years;Scientific Reports;2021-12

2. Recurrence of disease activity after fingolimod discontinuation in older patients previously stable on treatment;Multiple Sclerosis and Related Disorders;2021-06

3. Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials?;Expert Review of Neurotherapeutics;2020-10-10

4. Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules;Multiple Sclerosis and Related Disorders;2020-09

5. Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab;Multiple Sclerosis and Related Disorders;2020-04